Editas Medicine Inc

8EM

Company Profile

  • Business description

    Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

  • Contact

    11 Hurley Street
    CambridgeMA02141
    USA

    T: +1 617 401-9000

    E: [email protected]

    https://www.editasmedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    226

Stocks News & Analysis

stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.
stocks

Bookworm: Is this the secret to exceptional long-term returns?

Acceptance may be an investor’s best friend.
stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,934.3045.10-0.50%
CAC 407,834.5816.300.21%
DAX 4024,217.5078.43-0.32%
Dow JONES (US)44,901.92208.010.47%
FTSE 1009,120.3118.06-0.20%
HKSE25,388.35278.83-1.09%
NASDAQ21,108.3250.360.24%
Nikkei 22541,456.23370.11-0.88%
NZX 50 Index12,853.4648.330.38%
S&P 5006,388.6425.290.40%
S&P/ASX 2008,666.9042.50-0.49%
SSE Composite Index3,593.6612.07-0.33%

Market Movers